[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/13, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 오노, 바이오헤븐 ‘IgG 분해제 3종’ 亞권리 1억弗 L/I
[https://www.biospectator.com/news/view/30048](https://www.biospectator.com/news/view/30048)

 론자, 큐리언트 'CDK7' 이중페이로드 ADC 개발 "L/I 딜"
[https://www.biospectator.com/news/view/30057](https://www.biospectator.com/news/view/30057)

 티렉스, 나스닥 IPO 1.16억弗.."TNFR2 작용제 1상 개발"
[https://www.biospectator.com/news/view/30042](https://www.biospectator.com/news/view/30042)

 셀트리온, WAC 2026 참가..'졸레어 시밀러' 소개
[https://www.biospectator.com/news/view/30064](https://www.biospectator.com/news/view/30064)

 아사히, '新기전 HP저해제' 난치성 HSV "FDA 승인"
[https://www.biospectator.com/news/view/30046](https://www.biospectator.com/news/view/30046)

 온코닉, '체성분개선' 비만에셋 개발전략 "첫 공개"
[https://www.biospectator.com/news/view/30065](https://www.biospectator.com/news/view/30065)

 시티, 1.58억弗 IPO 추진..”올해 RNAi 에셋 3개 임상”
[https://www.biospectator.com/news/view/30049](https://www.biospectator.com/news/view/30049)

 BMS "오랜 시도", 'LPA1 약물' IPF 3상 "저용량만 효능"
[https://www.biospectator.com/news/view/30056](https://www.biospectator.com/news/view/30056)

 HLB 바이오스텝, 산업부 주관 'AI-NAMs' 국책과제 참여
[https://www.biospectator.com/news/view/30066](https://www.biospectator.com/news/view/30066)

 씨어스, 1100억 규모 CB 발행 결정.."해외 700억 투자"
[https://www.biospectator.com/news/view/30067](https://www.biospectator.com/news/view/30067)

 엘리시젠, 'VEGF AAV' 고용량 "효능 일관"..내년 美2b상
[https://www.biospectator.com/news/view/30063](https://www.biospectator.com/news/view/30063)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/13, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)